News & Updates

Show Multimedia Only

Atezolizumab + bevacizumab tops sorafenib in unresectable HCC

01 Jun 2020 by

The combination of atezolizumab and bevacizumab (atezo-bev) delivered better overall survival (OS) and progression-free survival (PFS) outcomes than sorafenib in patients with untreated, locally advanced metastatic or unresectable hepatocellular carcinoma (HCC), the phase III IMbrave150 trial has shown.

Atezolizumab + bevacizumab tops sorafenib in unresectable HCC

01 Jun 2020

Women have lower NAFLD risk than men but more likely to progress to advanced fibrosis

26 May 2020

Women are less likely to develop nonalcoholic fatty liver disease (NAFLD), although they are at higher risk of progression to advanced fibrosis once NAFLD is established as compared with men, a study reports.